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Abstract 
 
Objective To determine whether microglial activity, measured using translocator-
protein positron emission tomographic imaging (PET), is increased in unmedicated 
subjects presenting with sub-clinical symptoms indicating they are at ultra high risk of 
psychosis, and to determine if it is elevated in schizophrenia after controlling for a 
translocator specific genetic polymorphism. 
 
Method Here we use the second generation radioligand [11C]PBR28 and PET to 
image microglial activity in the brains of subjects at ultra high risk for psychosis. 
Subjects were recruited from early intervention centres. We also imaged a cohort of 
patients with schizophrenia and healthy controls for comparison, in total 56 subjects 
completed the study. At screening, subjects were genotyped to account for the 
rs6971 polymorphism in the gene encoding the 18Kd Translocator Protein. The main 
outcome measure was total grey matter [11C]PBR28 binding ratio, representing 
microglial activity. 
 
Results [11C]PBR28 binding ratio in grey matter was elevated in ultra high risk 
subjects, compared to matched controls, (p=0.004, F= 10.3, Cohen’s d >1.2), and 
was positively correlated with symptom severity (r= 0.730, p<0.01). Patients with 
schizophrenia also demonstrated elevated microglial activity with respect to matched 
controls (p<0.001, F= 20.8, Cohen’s d >1.7). 
 
Conclusion Microglial activity is elevated in schizophrenia and in subjects with sub-
clinical symptoms who are at ultra high risk of psychosis, and is related to at risk 
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symptom severity. These findings suggest that neuroinflammation is linked to the risk 
of psychosis and related disorders, and the expression of sub-clinical symptoms. 
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Introduction 
 
Schizophrenia is a severe psychiatric disorder characterised by psychotic and 
cognitive symptoms, and is a leading cause of global disease burden (1). It is 
generally preceded by a prodromal phase of attenuated psychotic symptoms and 
functional impairment (2). Subjects meeting standardised criteria for this phase have 
an ultra high risk for developing a psychotic disorder, in most cases schizophrenia 
(3). Approximately ~35% of high risk subjects will develop a psychotic disorder within 
24 months (4).  
 
Whilst the pathoaetiology of schizophrenia is not fully understood, there is increasing 
evidence for the involvement of neuroinflammatory processes. Microglia are the 
resident immune cells of the central nervous system and several lines of evidence 
indicate microglial involvement in the pathology of psychosis (5-7). In ultra high risk 
subjects, there are elevations in the levels of pro-inflammatory cytokines (8) which 
are also elevated in patients with schizophrenia (9). The levels of such peripheral 
markers have also been associated with the reductions in grey matter volume in both 
ultra high risk subjects (10) and patients with schizophrenia (11). Post-mortem 
investigation of brain tissue has found elevated microglial cell density (with a 
hypertrophic morphology) in schizophrenia compared with controls (5), particularly in 
the frontal and temporal lobes (12), although some studies have found no 
differences (13). However, as microglial activity is dynamic, post-mortem studies may 
miss alterations early in the development of the disease. 
 
Elevations in microglial activity can be measured in vivo with positron emission 
tomography (PET) using radioligands specific for the 18kD translocator-protein 
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(TSPO), which is expressed on microglia (14). Investigations using the first 
generation radiotracer (R)-[11C]PK11195 have revealed an increase in TSPO binding 
in medicated patients with schizophrenia when compared to healthy controls (6, 7). 
The first investigation of microglia using PET in schizophrenia, in a cohort of 10 
patients, revealed a total grey matter elevation of microglial activity in the five years 
following diagnosis (6). The most recent investigation in seven chronically medicated 
patients with schizophrenia using (R)-[11C]PK11195 demonstrated an elevation in 
hippocampal binding potential and a non-significant 30% increase in total grey 
matter binding potential (7).   
 
Whilst these studies indicate elevated microglial activity in schizophrenia, they 
included patients in whom the disorder was already established. It is therefore 
unknown whether this elevation predates the onset of, or becomes evident after, the 
first episode of frank psychosis.  
 
Therefore in the present investigation we seek to determine whether microglial 
activity is elevated in ultra high risk subjects using the novel TSPO radioligand 
[11C]PBR28. Our a priori hypothesis was that microglial activity would be elevated in 
the total grey matter in ultra high risk individuals compared to matched controls. An 
additional prediction was that this elevation would be evident in frontal and temporal 
cortical regions, brain areas that have been particularly implicated in ultra high risk 
pathophysiology (15). [11C]PBR28 is a second generation TSPO tracer with a higher 
affinity for TSPO than (R)-[11C]PK11195 (16). Recent in situ binding evidence shows 
that a genetic polymorphism (a C/T substitution at rs6971) influences the binding of 
TSPO tracers, including [11C]PBR28. This results in three TSPO binding profiles. 
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High affinity binders (HABs, C/C) have the greatest tracer affinity, low affinity binders 
(LABs , T/T) have a 50 fold reduction in affinity, and mixed affinity binders (MABs , 
C/T) express both HAB and LAB TSPO in approximately equal proportion (17). In 
view of this we included a cohort of patients to test the hypothesis that TSPO binding 
is elevated in schizophrenia after adjusting for this polymorphism, as this has not 
been taken into account previously. We also tested the secondary hypothesis that 
there would be a positive relationship between total grey matter microglial activity 
and symptom severity. 
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Methods 
 
The study was approved by the local research ethics committee and was conducted 
in accordance with the Declaration of Helsinki. After complete description of the 
study to the subjects, written informed consent was obtained. 
 
Subjects 
 
A total of 56 subjects were recruited and completed the study; 14 subjects meeting 
ultra high risk criteria, as assessed on the comprehensive assessment of the at risk 
mental state (CAARMS) (2), were recruited from OASIS (Outreach and Support in 
South London) (18) (Mean age ± SD: 24.3 ± 5.40; (M:F=7:7)). Fourteen age (± 5 
years) matched control subjects were recruited through newspaper and poster 
adverts. 14 subjects with schizophrenia (Mean age ± SD: 47.0 ± 9.31; (M:F=12:3)) 
were recruited from London mental health centres (South London and Maudsley 
NHS Foundation Trust). A further 14 age (± 5 years) matched healthy control 
subjects were recruited for comparison with this second cohort (Table 1.). 
 
All subjects met the following inclusion criteria: 
1. Aged 18+; 
2. No significant physical or psychiatric health contraindications on assessment 
and medical examination by a trained physician. 
 
Subjects were then screened based on the following exclusion criteria; 
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1. Exposure to any medications, including anti-inflammatory 
medications, in the last 1 month (see Supplemental Material for 
details). 
2. History of substance abuse/dependence as determined by the Structured 
Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 
IV (DSM-IV) (SCID) (19). 
3. Benzodiazepine use, whether prescribed or not (20). One subject was 
excluded due to a positive result for benzodiazepines on the scan day. 
4. History of head injury resulting in unconsciousness, or any physical 
medical condition associated with inflammation. 
5. At the time of screening, subjects were tested for TSPO genotype to 
determine binding status (17). Subjects with a LAB genotype were 
excluded. 
6. In ultra high risk and control subjects: antipsychotic medication exposure. 
7. Significant prior exposure to radiation 
8. Pregnancy or breast feeding. 
 
Healthy control subjects with a personal history of a psychiatric disorder or a first 
degree relative with schizophrenia or a psychotic illness were excluded. 
 
Clinical and neuropsychological measures 
 
At screening all subjects were assessed using the SCID (19). Ultra high risk subjects 
were assessed on the CAARMS (2) by a trained investigator and patients with a 
diagnosis of schizophrenia were assessed on the positive and negative syndrome 
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scale (PANSS) (21) by a clinician on the day of the PET scan. Depressive symptoms 
were assessed using the Beck Depression Inventory (BDI) (22).  
 
PET imaging 
 
An initial low dose transmission computer tomography (CT) scan (0.34 mSv) was 
acquired for attenuation and scatter correction using a Siemens Biograph™ 
TruePoint™ PET•CT scanner (Siemens Medical Systems, Germany). Subjects 
then received a bolus injection of [11C]PBR28 (mean Mbq activity ±SD: 325.31 ± 
27.03) followed by a 90-minute emission scan. PET data were co-registered with 
whole brain structural images acquired with a 3T magnetic resonance imaging (MRI) 
scanner (Trio, Siemens Medical Systems, Germany). A 32 channel coil was used for 
all but one scan, where a 12 channel coil was used instead.  
 
PET acquisition 
 
PET data were acquired dynamically over a 90-minute time window and binned into 
26 frames (durations: 8 x 15 s, 3 x 1 min, 5 x 2 min, 5 x 5 min, 5 x 10 min). Images 
were reconstructed using filtered back projection, which provides better data 
quality and signal-to-noise ratio over iterative methods (23), and corrected for 
attenuation and scatter. During the PET acquisition, arterial blood data were 
sampled via the radial artery using a combined automatic-manual approach. A 
continuous (one sample per second) sampling system (ABSS Allogg, Mariefred, 
Sweden) measured whole blood activity for the first 15 minutes of each scan (see 
on-line supplemental information for further details).  
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Structural MRI 
 
Each subject underwent a T1 weighted MRI brain scan. MRI images were used for 
grey/white matter segmentation and region of interest (ROI) definition. A 
neuroanatomical atlas (24) was co-registered on each subject’s MRI scan and PET 
image using a combination of Statistical Parametric Mapping 8 
(http://www.fil.ion.ucl.ac.uk/spm) and FSL (http://www.fsl.fmrib.ox.ac.uk/fsl) functions, 
implemented in MIAKATTM (http://www.imanova.co.uk). The primary region of interest 
was total grey matter. Secondary regions of interest were temporal and frontal lobe 
grey matter (12).  
 
Image analysis  
 
All PET images were corrected for head movement using nonattenuation-corrected 
images, as they include greater scalp signal, which improves re-alignment compared 
to attenuation-corrected images (25). Frames were realigned to a single ‘reference’ 
space identified by the individual T1 MRI scan. The transformation parameters were 
then applied to the corresponding attenuation-corrected PET frames, creating a 
movement-corrected dynamic image for analysis. Regional time-activity curves 
(TACs) were obtained by sampling the image with the coregistered atlas. Hence 
quantification of [11C]PBR28 tissue distribution was performed using the two tissue 
compartmental model accounting for endothelial vascular TSPO binding (2TCM-1K) 
(26),  as this has been shown to have improved performance compared with the two 
tissue compartmental model not accounting for endothelial binding (2TCM) (26). 
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Nevertheless, for completeness, we analysed the data using the 2TCM as well (see 
on-line supplemental information and Supplemental Table 1). Even after accounting 
for genotype, high inter-subject variability is seen in imaging with TSPO tracers. With 
PK11195 plasma protein binding is evident and may account for some levels of 
variability with TSPO imaging (27). Indeed TSPO ligand quantification approaches 
mostly use tissue reference methodologies (28). Analysis of PK11195 is 
conducted using simplified reference tissue models (SRTM) and supervised 
cluster analysis (29). This method is not applicable to second generation TSPO 
tracers, including PBR28, as the higher ligand affinity leads to appreciable 
endothelial binding in the blood brain barrier (BBB) (26). As a result, it is not 
possible to identify a supervised cluster for reference. Our outcome measure 
therefore was the distribution volume ratio (DVR, the ratio of the  in the ROI to  
in the whole brain) as this accounts for inter-subject variability in the input function. In 
secondary analyses, we tested the regional specificity of group changes by 
comparing DVR between groups in regions (the cerebellum and brainstem) where 
we did not expect marked inflammatory changes based on the post-mortem studies 
and grey matter changes seen in people at risk of psychosis (30). To ensure non-
specific effects of normalization, our parameters used to normalize the PET 
signal were tested for group differences. There are no differences in blood or 
normalization regions used (see Supplemental Table 2). 
 
Statistical analysis 
  
Data, other than for gender and genotype, were shown to have a normal distribution 
following a Shapiro-Wilk test (31). Hence parametric tests were implemented for all 
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but gender and affinity analyses, where a Mann-Whitney U test was used. 
Demographic data and tracer activity data were analysed using independent-
samples t-tests. Multiple analysis of covariance (ANCOVA) with Bonferroni 
correction (32) was used to determine whether there was an effect of group on 
[11C]PBR28 binding associated microglial activity in the total grey matter, frontal lobe, 
and temporal lobe. There is data to suggest that cortical microglial density, hence 
TSPO binding, is elevated with aging (33), which is also evident in our data (see 
Supplemental Table 3). For this reason, we performed group level analysis using 
age as a covariate. There is a significantly higher binding of tracer in HABs than 
MABs and the variation in signal from HAB and MAB subjects is high, with a 
large degree of overlap across the binding statuses (Supplemental Figure 3). 
Hence we pooled the binding statuses in our groups and co-varied for 
genotype in our analysis. (17). For all statistical comparisons alpha was set at a 
0.05 threshold (two-tailed) for significance. Statistical analysis was performed using 
SPSS 21 (IBM, USA). Partial correlation analysis was used to test the association of 
microglial activity with symptom severity and total grey matter volumes, with age and 
affinity as covariates of no interest.  
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Results 
  
Demographic Comparisons and Tracer Dosing 
 
No significant demographic differences between the two groups of controls and 
respective patient groups were observed (Table 1). There were no differences in the 
injected dose, injected mass, specific activity, parent plasma fraction or plasma over 
blood ratio between ultra high risk subjects or patients with schizophrenia and their 
respective controls (Supplemental Table 4).  
 
[11C]PBR28 distribution in total grey matter regions 
 
The [11C]PBR28  distribution volume ratios in total grey matter, frontal lobe and 
temporal lobe grey matter were significantly increased in ultra high risk when 
compared with matched control subjects (Figure 1 A and Table 2).  Similarly, patients 
with a diagnosis of schizophrenia had elevated [11C]PBR28 DVRs in total, frontal 
lobe and temporal lobe grey matter with respect to matched control subjects (Figure 
1 B and Table 2). Secondary analysis to investigate regional specificity revealed no 
difference between ultra high risk or schizophrenia and respective controls in 
cerebellar or brainstem DVR (Table 2). Representative PET images of control, ultra 
high risk and patients with schizophrenia are presented in Figure 1 C. When 
comparing regions using VT, with either 2TCM or 2TCM-1K, no significant 
group difference was observed (supplemental Table 5). 
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Two subjects in the ultra high risk group had taken citalopram in the past. 
However only one was using the medication at the time of scan, and no other 
UHR subjects had taken psychotropic drugs. Re-analysis excluding the two 
subjects who had taken citalopram did not alter the significant elevation in 
[11C]PBR28 DVR in the high risk group in the total (F=6.601, p=0.018) and 
frontal lobe (F=5.392, p=0.030) grey matter but the finding in the temporal 
cortex was no longer significant (p=0.149). 
 
Genotype specific analysis 
 
In further sensitivity analyses, we repeated the analyses separately for HABs 
and MABs in the UHR. This showed that the elevation in the ultra high subject 
was present irrespective of whether the analysis was restricted to HABs or 
MABs (Supplemental Table 6 and Suppl mental Figure 3). 
 
Relationship between [11C]PBR28 distribution and symptom severity 
 
In ultra high risk subjects, there was a positive correlation between the total 
CAARMS symptom severity score and [11C]PBR28 DVR in total grey matter (r = 
0.730, p = 0.011, Figure 2). No correlation was observed between [11C]PBR28 
DVR in total grey matter and duration of ultra high risk symptoms (r= -0.086, p= 
0.802). In patients with schizophrenia, there was no significant correlation between 
total grey matter DVR and total PANSS score (Supplemental Figure 2). There was 
no relationship between depressive symptom severity (Beck Depression Inventory 
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score) and total grey matter DVR in either patients with schizophrenia (r= 0.478 p= 
0.162) or ultra high risk subjects (r=-0.339 p= 0.506).  
 
Exploratory analysis of DVR normalization 
 
To evaluate whether our findings were influenced by the signal used for 
normalization, we conducted exploratory analyses using the cerebellum and 
white matter as alternative normalization regions. Cerebellar normalization did 
not alter the major regional findings (frontal lobe p=0.001; temporal lobe 
p=0.006). White matter normalization performed similarly to the cerebellum 
(see supplemental table 7).  
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Discussion 
 
Our main finding is that [11C]PBR28 binding ratio, a marker of microglial activity, is 
elevated in people at ultra high risk of psychosis, with a large effect size (Cohen’s d 
>1.2). Furthermore [11C]PBR28 binding ratio was associated with the severity of 
symptoms in ultra high risk subjects, linking elevated microglial activity to the 
expression of sub-clinical psychotic symptoms. Importantly we found no relationship 
with depressive symptoms, suggesting elevated microglial activity is specific to the 
development of psychotic-like symptoms, rather than psychiatric symptoms in 
general. It would be valuable to examine change in [11C]PBR28 signal during 
the course of the prodromal period to determine if there is a change during the 
prodromal phase. As the ultra high risk subjects, who had recently presented to 
psychiatric services, were medication naïve and had no history of psychotic disorder, 
these findings cannot be attributed to effects of previous illness or its treatment. 
Interestingly, at the time of writing, one ultra high risk subject has transitioned 
to first episode psychosis. This subject had the highest total grey matter 
[11C]PBR28 signal in the cohort (DVR=2.14). Follow up of the remaining 
subjects is required to determine the role of elevated TSPO availability in the 
onset of psychosis. 
 
The present findings are consistent with recent evidence of elevated peripheral 
inflammatory markers in people at high risk of psychosis (8, 10), and suggest that 
elevated microglial activity predates the onset of frank psychosis. We also found 
evidence of elevated microglia activity in people with schizophrenia relative to 
controls with a large effect size (Cohen’s d >1.7). This extends previous PET studies 
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which have not controlled for TSPO genotype (34), a potential confound as genotype 
influences binding, by showing that TSPO binding is elevated after controlling for 
TSPO genotype. Our findings are also consistent with the findings of a post-
mortem study in schizophrenia, which also used PBR28. However, because it 
was in vitro, was able to use a two-point assay to quantify specific PBR28 
binding to show elevated PBR28 binding in schizophrenia (35). We did not find 
the same symptom correlation in schizophrenia as we did in ultra high risk subjects. 
This may be due to the fact that these patients were not acutely unwell. 
 
Limitations 
 
Antipsychotic treatment is a potential confound in the schizophrenia group (see 
Supplemental Table 6) but not the ultra high risk group. There is growing evidence to 
suggest an influence of antipsychotic medication on microglial cell dynamics, 
including evidence that antipsychotics may reduce microglial activity (36-38). Hence 
in future studies it would be preferable to investigate patients with schizophrenia who 
were medication naïve.  
 
In this investigation, we have used an approach to analysis (accounting for 
endothelial and vascular binding), which has been shown to be more reliable 
than alternative approaches (26). This was applied in a standardized 
automated manner across groups, and also applied to control regions (brain 
stem and cerebellum) to examine the specificity for our findings. A limitation of 
all current approaches to imaging microglia, including with [11C]PBR28, is that the 
outcome measure is VT. Thus the elevation in grey matter could reflect increased 
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non-specific tracer binding as well as biological signal. However, blocking studies 
have shown that a substantial proportion of VT for [11C]PBR28 is specific 
binding to the TSPO (39), although the proportion in schizophrenia remains to 
be determined.  
 
In our sample, plasma input analysis results in a ~30% level of VT variability 
using the 2TCM approach. This variability is due in part to a small free fraction 
(fp), which has been reported to introduce 29% variability (see Supplemental 
Table 8 and (26)). This being the case, the noise and measurement error from fp 
appears to be greater than the component it represents (40) and obscures the 
signal difference in our cohorts. Indeed, the variability of fp in our cohorts 
reaches 35% (9.9± 3.5), resulting in a large VT variability. Further work is 
needed to assess the full consequences of fp variability. Our normalization 
approach does however remove individual variation in fp, thus reducing inter-
subject variability. 
 
We used the distribution volume ratio (DVR), in this case with whole brain 
signal as our normalization region, as our outcome measure. We also showed 
that the main findings remained significant when other regions were used, 
suggesting that the findings are robust to the method of normalization. The 
use of DVR analysis is a standard approach in PET imaging that has recently 
been applied to second generation TSPO tracers (41, 42), including using 
whole brain normalization (43), as well as to the first generation TSPO tracer 
PK11195 (44, 45). Preclinical studies have demonstrated that the DVR 
approach is able to detect microglial changes due to inflammatory stimuli and 
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confirmed that elevated DVR signal corresponds to elevated levels of TSPO 
and other markers of microglia measured ex vivo using immunohistochemistry 
and/or autoradiography (46-49). These preclinical studies thus indicate the 
functional significance of elevated [11C]PBR28 DVR and support further in vivo 
investigation in patients. 
 
Normalisation by the whole brain VT raises a conceptual issue as the whole 
brain VT includes the grey matter VT as one constituent. The whole brain VT 
also includes the VT in other tissue compartments including white matter and 
sub-cortical structures. Thus the elevation we see in the ultra high risk and 
schizophrenia groups could indicate a reduced VT in one or more of these 
other compartments. Further work to investigate changes in these 
compartments, for example using selective TSPO blockers, is required to test 
this interpretation. 
 
Preclinical studies have demonstrated that the DVR approach is able to detect 
microglial changes due to inflammatory stimuli and confirmed that elevated 
DVR signal corresponds to elevated levels of TSPO and other markers of 
microglia measured ex vivo using immunohistochemistry and/or 
autoradiography (46-49). These preclinical studies thus indicate the functional 
significance of elevated [11C]PBR28 DVR but further in vivo investigation in 
patients will be required to confirm the functional significance. 
 
The normalization approach would likely account for global group differences in non-
specific binding but we cannot exclude a grey matter selective increase in non-
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specific binding contributing to the elevations seen. Whilst the signal-to-noise ratio of 
[11C]PBR28 PET imaging is better relative to first generation tracers, it remains 
relatively low. However this noise would obscure a difference between groups, so is 
unlikely to account for our findings. In this study we did not correct for possible partial 
volume effects. Given that brain volume is generally reduced in schizophrenia, these 
would tend to underestimate the elevations observed here and not account for our 
group differences. There is a relatively higher binding in control subjects matched to 
patients with schizophrenia over those matched to the ultra high risk group. This can 
be explained in part by age associated increases in TSPO but also by an increased 
number of MABs in the ultra high risk matched controls. Finally, it is important to note 
that not all the ultra high risk subjects will go on to develop a psychotic disorder and 
we will conduct clinical follow-up to determine whether the elevated microglial activity 
is specific to the development of the disorder or risk factors for psychosis.  
 
Implications 
 
Whilst TSPO may be expressed on astrocytes (50) and some neuronal sub-types 
(51), it is predominantly expressed on microglia (52). The direct biological 
relationship between microglia and TSPO binding in vivo is not fully understood. 
However, in non-human primates inflammation induced increases in microglial 
activity cause marked increases in [11C]PBR28 signal, confirmed post mortem to be 
largely due to microglial binding (53). Microglia perform immune surveillance roles, 
mount inflammatory response to injury (54) and are involved in synaptic modulation 
in experience dependent plasticity (55). Interpretation of elevated activity is therefore 
complex and not defined by ‘activated’ or ‘resting’. The elevations presented here 
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might reflect a protective response triggered by associated pathology, such as 
glutamatergic excitotoxicity (56) or indicate a primary neuroinflammatory process 
linked to risk factors for psychosis and the development of sub-clinical symptoms. 
When our findings are interpreted with evidence that anti-inflammatory drugs are 
effective in schizophrenia (57), particularly in addressing early negative symptoms 
(58), they suggest a neuroinflammatory process is involved in the development of 
psychotic disorders. Whilst this indicates that anti-inflammatory treatment may be 
effective in preventing the onset of the disorder, further studies are required to 
determine the clinical significance of elevated microglial activity. 
 
Conclusions 
 
Here we provide, to our knowledge, the first evidence of elevated brain microglial 
activity in people at ultra high risk of psychosis, and show that greater microglial 
activity is associated with greater symptom severity. We also demonstrate the first in 
vivo elevations of TSPO binding in schizophrenia with a second generation tracer 
after adjusting for TSPO genotyping. These findings are consistent with increasing 
evidence that that there is a neuroinflammatory component in the development of 
psychotic disorders, raising the possibility that it plays a role in its pathogenesis.  
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Patient perspectives 
 
Patient 1 – Clinical vignette 
 
‘Well I like the idea of taking part in research. It’s nice to try to help people find out 
what’s wrong.’ 
 
Patient 1 was the first patient I’d met while conducting clinical academic research. I 
had spoken to her care coordinator with the local mental health trust in South 
London and after talking on the phone, she visited the Hammersmith Hospital. We 
had a long chat about the research and I, with support from Dr Selvaraj, screened 
her for the study. Patient 1 had lived in London for her adult life and relied greatly on 
support from her family and the local mental health trust, she had been diagnosed 
with schizophrenia 13 years ago, at which point she was placed under section 
(involuntary admission). Patient 1 spoke of her experience of schizophrenia and her 
struggles to find a suitable medication, she was experiencing extrapyramidal side 
effects from her current regime of paliperidone, however was ‘sticking with it for 
now’. Following the MRI scan, she seemed glad to be out of such a confined space 
and responded in a more positive way to the open space of the PET scanner. I 
phoned patient 1 after 24 hours to check on the arterial site condition which was, ‘a 
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little bruised, but getting better.’ We stayed in touch until honorarium reached her 
account, at which point she asked to be told of more research opportunities. 
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Figures 
 
Figure 1. Microglial activity measured with PET in ultra high risk subjects, 
patients with schizophrenia and matched controls
 
Significant difference between experimental (red) and control (blue) groups, 
ANCOVA (covarying for age and genotype). A: a (df=21 p=0.004), b (df=21 p=0.030), 
c (df=21 p=0.047); B: d (df=21 p<0.001), e (df=21 p=0.005), f (df=21 p=0.001); C 
representative [11C]PBR28 PET image from a subject from each group. 
 
  
A 
B 
C 
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Figure 2. Microglial activity and symptom scores in ultra high risk subjects 
 
 
Significant correlation between measures. Partial correlation including age and 
genotype as covariates (N=13, data were missing for 1 subject r= 0.730, p= 0.011). 
Highlighted subject, transition case. 
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Tables 
 Control Stdev Ultra high 
risk 
Stdev p-value Control Stdev Schizophrenia Stdev p 
 N = 14  N = 14  - N=14  N = 14  - 
Age in years 28.14 7.99 24.29 5.40 0.133a 46.21 13.62 47.00 9.31 0.982a 
Years of 
education 
14.8 3.0 14.3 1.6 0.344a 12.3 3.0 12.2  2.0 0.374a 
Gender (M:F) 10:4  7:7  0.352 b 12:3  12:3  1.000b  
TSPO genotype 
(HAB) 
10  7  0.352 b 14  13  0.541b 
CAARMS/ 
PANSS 
          
Positive - - 11.2 4.5  - - 17.0 6.1 - 
Negative - - 6.1 4.3  - - 14.1 4.0 - 
General - - 19.1 12.3  - - 32.6 8.7 - 
Total - - 49.5 21.6  - - 63.7 18.1 - 
 
Table 1 – Demographic characteristics of experimental and control subjects, aindependent samples t-test. bMann-Whitney U test. 
Symptom scales measured in high risk subjects on the CAARMS (comprehensive assessment of the ‘at risk mental state’) and in 
schizophrenia on the PANSS (positive and negative syndrome scale).
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Mean 
Regional 
DVR of 
[11C]PBR28 
Control Stdev Ultra high 
risk 
Stdev F P Cohen’s d Control Stdev Schizophrenia SD F p Cohen’s d 
Total grey 
Matter 
2.032  0.017 2.088  0.021 10.332 0.004 1.244 2.465  0.020 2.557  0.014 20.802 <0.001 1.769 
Frontal lobe 2.000 0.038 2.087  0.026 5.339 0.030 0.894 2.489  0.037 2.606  0.025 9.883 0.005 1.245 
Temporal 
lobe 
1.914  0.041 2.001  0.028 4.417 0.047 0.829 2.282  0.065 2.518  0.044 13.089 0.001 1.430 
Cerebellum  2.307  0.055 2.287  0.081 0.062 0.805 - 2.863  0.060 2.873  0.063 0.015 0.905 - 
Brain stem 2.291 0.191 2.489 0.28 0.500 0.487 - 2.514 0.154 2.097 0.234 3.194 0.088 - 
 
Table 2 – Microglial activity, as measured by PBR28 distribution volume ratio, is elevated in subjects at ultra high risk of psychosis 
(df=21 p=0.004) and patients with schizophrenia (df=21 p<0.001) in the total grey matter, frontal and temporal cortical regions of 
interest but not in control regions (the cerebellum and brainstem). The mean regional distribution volume ratios are shown for each 
group together with those for matched controls. The results of the ANCOVA covarying for age and translocator-protein genotype are 
shown for each case-matched control comparison
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